吉林省西点药业科技发展股份有限公司 关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）定于 2025 年 9 月 2 日（星期二）14:30 召开 2025 年第一次临时股东会，本次会议采取现场表 决与网络投票相结合的方式召开，现将有关事项通知如下： 一、 召开会议的基本情况 1、会议届次：2025 年第一次临时股东会 2、会议召集人：董事会。 3、会议召开的合法、合规性：第八届董事会第十二次会议审议通过了关于 召开本次股东会的议案。本次股东会会议的召开符合有关法律、行政法规、部 门规章、规范性文件和《公司章程》的有关规定。 证券代码：301130 证券简称：西点药业 公告编号：2025-057 4、会议召开的日期、时间： （1）现场会议：2025 年 9 月 2 日（星期二）14:30 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2025 年 9 月 2 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15: ...

证券代码：301130 证券简称：西点药业 公告编号：2025-054 吉林省西点药业科技发展股份有限公司 第八届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、会议召开情况 吉林省西点药业科技发展股份有限公司（以下简称"公司"）第八届董事会 第十二次会议于 2025 年 8 月 14 日 9:30 以现场结合通讯方式在吉林省长春市卫 星路 1471 号公司会议室召开。本次会议通知于 2025 年 8 月 4 日以邮件、电话、 书面等方式送达全体董事。会议由董事长张俊先生主持，应出席董事 9 名，实际 出席董事 9 名，其中以通讯方式参会并表决的董事有刘淑敏女士、申太根先生。 公司高级管理人员、保荐代表人列席了会议。 会议的召开符合《中华人民共和国公司法》和《公司章程》的规定，会议合 法有效。 二、会议审议情况 经与会董事认真审议并表决，审议了如下事项： （一）审议通过《关于公司<2025 年半年度报告>全文及其摘要的议案》 董事会认为：《2025 年半年度报告》全文及其摘要编制和审议的程序符合法 律、行政法规和中国证券监督管理 ...

Core Points - The report summarizes the financial performance and operational status of Jilin Xidian Pharmaceutical Technology Development Co., Ltd. for the first half of 2025, highlighting a slight decrease in revenue but an increase in net profit [1][2]. Financial Performance - Operating revenue for the reporting period was CNY 128,311,809.27, a decrease of 0.51% compared to the same period last year [1]. - Net profit attributable to shareholders was CNY 24,944,585.08, reflecting a growth of 2.02% year-on-year [1]. - Net cash flow from operating activities increased by 3.49% to CNY 33,713,141.57 [1]. - Basic earnings per share rose by 7.77% to CNY 0.3261, while diluted earnings per share increased by 5.43% to CNY 0.3261 [1]. - The weighted average return on equity was 2.73%, up from 2.56% in the previous year [1]. Asset and Equity Status - Total assets at the end of the reporting period were CNY 1,055,706,506.89, a decrease of 0.65% from the previous year [1]. - Net assets attributable to shareholders increased by 0.56% to CNY 910,831,590.25 [1]. Shareholder Information - The largest shareholder, Zhang Jun, holds 25.66% of the shares, amounting to 19,627,034 shares [2]. - Other significant shareholders include Dingdian Investment Management (7.86%) and Zhuhai Hengqin Yanhe Health Technology (4.83%) [2][3]. - The report indicates that there are no changes in the controlling shareholder or actual controller during the reporting period [4]. Important Events - The company received approval for several drug applications, including sodium hyaluronate eye drops and antiviral tablets, which may enhance its product portfolio and market position [6].

Core Viewpoint - Jilin Province Xidian Pharmaceutical Sci-Tech Development Co., Ltd. reported a slight decrease in revenue but an increase in net profit, indicating a focus on improving core business profitability and market expansion strategies [7][24]. Financial Performance - The company's operating income for the reporting period was 128,311,809.27 yuan, a decrease of 0.51% compared to the same period last year [7][24]. - Net profit attributable to shareholders was 24,944,585.08 yuan, an increase of 2.02% year-on-year [7][24]. - The net profit after deducting non-recurring gains and losses was 23,386,006.42 yuan, reflecting a growth of 12.26% compared to the previous year [7][24]. - Basic earnings per share increased by 7.77% to 0.3261 yuan [7][24]. Business Overview - The company primarily engages in the research, production, and sales of chemical pharmaceutical raw materials and formulations, focusing on chronic disease treatments prevalent among the elderly, iron supplementation, circulatory disorders, and psychiatric medications [9][11][15]. - The company has developed a strong product pipeline, holding 29 formulation varieties and 16 raw material drug registrations [15]. Market Trends - The pharmaceutical industry is experiencing structural changes, with a significant increase in mergers and acquisitions, driven by technological innovation and globalization [10]. - The demand for pharmaceuticals remains robust due to an aging population and increasing healthcare needs, making the industry less susceptible to economic fluctuations [10]. Product Development - The company is recognized for its core products, including the unique Rhizoma Smilacis capsules and compound ferrous sulfate folic acid tablets, which have received national patents and are positioned as leading treatments in their respective categories [12][15]. - The company is actively expanding the clinical applications of its products, particularly in treating complications related to diabetes and enhancing its market presence in the iron supplement sector [12][15]. Strategic Initiatives - The company has shifted its sales strategy from an agency model to a self-operated model for key products, enhancing its marketing capabilities and establishing a more direct connection with healthcare providers [23]. - The company emphasizes technological advancement and product innovation as core drivers of its development strategy, focusing on the elderly healthcare market and chronic disease treatments [18][23].

关于召开 2025 年第一次临时股东会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）定于 2025 年 决与网络投票相结合的方式召开，现将有关事项通知如下： 一、 召开会议的基本情况 召开本次股东会的议案。本次股东会会议的召开符合有关法律、行政法规、部 门规章、规范性文件和《公司章程》的有关规定。 证券代码：301130 证券简称：西点药业 公告编号：2025-057 吉林省西点药业科技发展股份有限公司 （3）公司聘请的律师； （4）根据相关法规应当出席股东会的其他人员。 二、 会议审议事项 本次股东会提案编码表： （1）现场会议：2025 年 9 月 2 日（星期二）14:30 （2）网络投票：通过深圳证券交易所交易系统进行网络投票的具体时间 为：2025 年 9 月 2 日的交易时间，即 9:15-9:25，9:30-11:30 和 13:00-15:00；通 过深圳证券交易所互联网投票系统（http://wltp.cninfo.com.cn）投票的具体时间 为：2025 年 9 月 2 日 ...

格隆汇8月14日丨西点药业(301130.SZ)公布2025年半年度报告，上半年公司实现营业收入1.28亿元，同 比下降0.51%；归属于上市公司股东的净利润2494.46万元，同比增长2.02%；归属于上市公司股东的扣 除非经常性损益的净利润2338.60万元，同比增长12.26%；基本每股收益0.3261元。 ...

`[Task]` You are a senior financial report analysis assistant. Please carefully read the following outline content and generate a clear and professionally structured report outline in Markdown format, with the following requirements: `[1] Structural Requirements (Must Follow)` - Please translate the report content into English first before proceeding to the next step, Be sure to pay attention to the units in the content. In English, make sure not to mistake billion, million - Please use appropriate heading styles based on the outline's chapter level (e.g., for first-level, for second-level). For each chapter, provide a concise one-sentence summary (around 100 characters) that captures the core content, using precise language while avoiding redundant information or repeated listing of sub-items - Add page-jump links for each "chapter title" in the format: `[Chapter Title](index=page_num&type=section&id=item_id)` - `page_num` must strictly use the starting page (`start_page`) from the "outline" for the corresponding chapter - Note that `item_id` requires URL encoding for spaces and special characters Complete example: `[Legal Proceedings and Risk Factors](index=32&type=section&id=Item%201%20%26%201A.%20Legal%20Proceedings%20and%20Risk%20Factors)` - For `key_points` of "insight" type, display as unordered lists, with bold formatting for key metrics and conclusions where appropriate - For `key_points` of "table" type, use Markdown tables, with table titles as subheadings (not unordered lists), and preferably include units in column headers - If a `key_point` has chunk references, append references in `[1],[2],[3],[4]` format at the end of the sentence in ascending order. Do not add references to tables! Reference format: `[chunk_num](index=chunk_num&type=chunk)` ========= Example: Operating cash flow decreased by $1.47 billion, primarily due to lower net income (excluding non-cash items)[241](index=241&type=chunk)[242](index=242&type=chunk) `[2] Language Style Requirements` - Use formal written language, avoid explanatory phrases like "the following" or "this chapter introduces" - Chapter summaries should be concise single sentences, without elaboration or repeating key_points content - Do not add "Report Title" or other redundant prefixes - Use professional financial terminology and expressions - Please output in English，Avoid using periods at the end of sentences `[3] Output Example:` Part I [Business Overview](index=4&type=section&id=Item%201.%20Business) The company focuses on developing high-performance computing platforms with core products covering computing, networking, and AI directions - Revenue primarily driven by AI accelerators and data center business, with **45% growth in FY2024**[13](index=13&type=chunk) - Data center segment accounts for **65% of total revenue**, serving customers including AWS and Azure[15](index=15&type=chunk) [Risk Factors](index=13&type=page&id=Item%201A.%20Risk%20Factors) The company faces multiple risks in supply chain, regulations, and international trade - Increased dependency on core suppliers like TSMC elevates supply disruption risks[22](index=22&type=chunk) - US export controls may impact product sales to Chinese markets[23](index=23&type=chunk) outline: ```json [{"level": 1, "title": "重要提示、目录和释义", "item_id": "第一节 重要提示、目录和释义", "summary": null, "children": [{"level": 2, "title": "重要提示", "item_id": "重要提示", "summary": "公司董事会、高级管理人员保证半年度报告内容的真实、准确、完整，并承担法律责任。公司负责人、主管会计工作负责人及会计机构负责人声明财务报告真实、准确、完整。所有董事均已出席审议会议。报告涉及前瞻性内容，不构成实质承诺，投资者应注意风险。公司计划不派发现金红利，不送红股，不以公积金转增股本。", "children": [], "end_page": 2, "key_points": [{"type": "insight", "content": "公司董事会及高级管理人员保证报告内容的真实、准确、完整，并承担法律责任。", "chunk_num": [3]}, {"type": "insight", "content": "公司负责人、主管会计工作负责人及会计机构负责人声明财务报告真实、准确、完整。", "chunk_num": [3]}, {"type": "insight", "content": "公司计划不派发现金红利，不送红股，不以公积金转增股本。", "chunk_num": [4]}], "start_page": 2}, {"level": 2, "title": "目录", "item_id": "目录", "summary": "本节提供了报告的整体结构，包括重要提示、公司简介、管理层讨论与分析、公司治理、重要事项、股份变动及股东情况、债券相关情况和财务报告等八个主要章节及其对应的页码。", "children": [], "end_page": 4, "key_points": [{"type": "insight", "content": "报告包含八个主要章节，涵盖公司运营、财务、治理及重要事项等多个方面。", "chunk_num": [6]}], "start_page": 3}, {"level": 2, "title": "释义", "item_id": "释义", "summary": "本节对报告中使用的关键术语进行了定义，包括公司名称、监管机构、货币单位、药品分类（处方药、非处方药）、药品批准文号、原料药、制剂、精神障碍相关用药、通用名、商品名以及报告期等，确保读者对专业术语的理解一致性。", "children": [], "end_page": 6, "key_points": [{"type": "insight", "content": "报告中对“本公司”、“中国证监会”、“深交所”、“国家药监局”等常用机构和术语进行了明确定义。", "chunk_num": [12]}, {"type": "insight", "content": "详细解释了医药行业特有术语，如“处方药”、“非处方药/OTC”、“药品批准文号”、“原料药”、“制剂”、“抗精神病用药”等。", "chunk_num": [12]}, {"type": "insight", "content": "明确了“报告期”为2025年1月1日至2025年6月30日，以及“上年同期”等时间概念。", "chunk_num": [12]}], "start_page": 5}], "end_page": 6, "start_page": 2}, {"level": 1, "title": "公司简介和主要财务指标", "item_id": "第二节 公司简介和主要财务指标", "summary": null, "children": [{"level": 2, "title": "公司简介", "item_id": "一、公司简介", "summary": "吉林省西点药业科技发展股份有限公司（股票简称：西点药业，股票代码：301130）在深圳证券交易所上市，法定代表人为张俊。", "children": [], "end_page": 7, "key_points": [{"type": "insight", "content": "公司股票简称“西点药业”，股票代码“301130”，在深圳证券交易所上市。", "chunk_num": [16]}, {"type": "insight", "content": "公司法定代表人为张俊。", "chunk_num": [16]}], "start_page": 7}, {"level": 2, "title": "联系人和联系方式", "item_id": "二、联系人和联系方式", "summary": "本节提供了公司董事会秘书张银姬和证券事务代表郑圣玉的联系信息，包括联系地址、电话、传真和电子信箱，便于投资者和相关方进行沟通。", "children": [], "end_page": 7, "key_points": [{"type": "insight", "content": "董事会秘书为张银姬，证券事务代表为郑圣玉。", "chunk_num": [17]}, {"type": "insight", "content": "联系地址均为吉林省长春市卫星路1471号，电话为0431-80606619。", "chunk_num": [17]}], "start_page": 7}, {"level": 2, "title": "其他情况", "item_id": "三、其他情况", "summary": "报告期内，公司的注册地址、办公地址、网址、电子信箱、信息披露及备置地点以及注册情况均无变化，具体信息可参考2024年年报。", "children": [], "end_page": 7, "key_points": [{"type": "insight", "content": "公司联系方式、信息披露及备置地点、注册情况在报告期内均无变化。", "chunk_num": [18, 19, 20]}], "start_page": 7}, {"level": 2, "title": "主要会计数据和财务指标", "item_id": "四、主要会计数据和财务指标", "summary": "报告期内，公司营业收入略有下降，但归属于上市公司股东的净利润和扣除非经常性损益的净利润均实现增长，经营活动现金流量净额和基本每股收益也有所提升，总资产和归属于上市公司股东的净资产保持稳定。", "children": [], "end_page": 8, "key_points": [{"type": "table", "title": "主要会计数据和财务指标（本报告期 vs 上年同期）", "content": "| 指标 | 本报告期 (元) | 上年同期 (元) | 同比增减 (%) |\n| :--- | :--- | :--- | :--- |\n| 营业收入 | 128,311,809.27 | 128,969,119.73 | -0.51% |\n| 归属于上市公司股东的净利润 | 24,944,585.08 | 24,451,714.25 | 2.02% |\n| 归属于上市公司股东的扣除非经常性损益的净利润 | 23,386,006.42 | 20,831,409.30 | 12.26% |\n| 经营活动产生的现金流量净额 | 33,713,141.57 | 32,576,623.33 | 3.49% |\n| 基本每股收益 (元/股) | 0.3261 | 0.3026 | 7.77% |\n| 稀释每股收益 (元/股) | 0.3261 | 0.3093 | 5.43% |\n| 加权平均净资产收益率 | 2.73% | 2.56% | 0.17% |\n| **指标** | **本报告期末 (元)** | **上年度末 (元)** | **本报告期末比上年度末

西点药业公告，2025年上半年营业收入1.28亿元，同比下降0.51%。净利润2494.46万元，同比增长 2.02%。公司计划不派发现金红利，不送红股，不以公积金转增股本。 ...

Core Viewpoint - The company emphasizes innovation as its core driving force and employs a dual-track strategy of "independent research and joint development" to advance its R&D efforts in innovative drug development, particularly focusing on areas such as anemia and the circulatory system [1] Group 1: R&D Strategy - The company is committed to enhancing its pipeline through various strategies, including technology introduction and changes in drug marketing authorization holders [1] - The core ongoing project involves expanding new indications for the drug Ruixiangsu capsules, with recent achievements including two invention patents for its applications in treating lymphatic reflux disorders and viral pneumonia, both currently in preclinical research [1] Group 2: Product Development - In addition to developing novel small molecule compounds, the company is also focused on improving existing products to enhance their clinical value and lifecycle [1] - The company plans to continuously increase investment in innovative drug R&D and expand its reserve of new technologies and products [1] Group 3: Communication and Reporting - The company will provide timely updates on its progress through regular reports and interim announcements [1]

证券代码：301130 证券简称：西点药业 公告编号：2025-051 吉林省西点药业科技发展股份有限公司 关于使用闲置募集资金及自有资金进行现金管理和委托理财 到期赎回并继续进行现金管理和委托理财的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 吉林省西点药业科技发展股份有限公司（以下简称"公司"）于 2025 年 1 月 20 日召开第八届董事会第十次会议、第八届监事会第十次会议，分别审议通 过了《关于使用部分闲置募集资金进行现金管理及使用部分闲置自有资金进行现 金管理和委托理财的议案》，同意公司在确保募集资金投资项目建设正常进行和 资金安全的前提下，使用额度不超过人民币 1.0 亿元的部分闲置募集资金（含超 募资金）进行现金管理，公司及全资子公司在确保不影响公司日常经营的前提下， 使用额度不超过人民币 1.5 亿元的部分闲置自有资金进行现金管理和委托理财， 用于购买安全性高、流动性好、期限不超过 12 个月的短期投资理财产品。使用 期限自董事会审议通过之日起 12 个月内有效。在上述额度和期限内，资金可循 环滚动使用。具体内容详见公司在巨潮资讯网上 ...